Immunosuppressive therapy for patients with refractory anemia.
2001
Trials of immunosuppressive
therapyhave been reported in some case reports of hypoplastic
myelodysplastic syndrome(MDS). In this study, we gave immunosuppressive
therapiesto eight patients with normo- or hyperplastic MDS of refractory anemia subtype without karyotypic abnormalities and analyzed the
HLA-DRB1type or the presence of
paroxysmal nocturnal hemoglobinuria(PNH) neutrophils in these patients. Cyclosporin A (CyA)
therapywas effective for improving
cytopeniain four of the eight MDS patients. While the side effects of CyA were mostly mild and transient, one patient demonstrated karyotypic abnormality following CyA
therapyand accelerated to refractory anemia with an excess of blasts. Additional antithymocyte globulin (ATG)
therapywas effective in one of three nonresponders to CyA
therapy. One patient died due to leukemic transformation after ATG
therapy. When we analyzed the correlation between the response to CyA
therapyand the
HLA-DRB1type, there were more responders with DRB1*1501 (three of four patients) than without (one of four patients), but a statistically significant difference was not evident between the two groups. In addition, the presence of PNH neutrophils was not correlated with the response to CyA and/or ATG
therapy. These results indicate the usefulness of immunosuppressive
therapieseven for normo- or hyperplastic MDS patients. Further trials using more patients with a long follow-up period would be worthwhile in order to clarify the possibility of disease progression and in order to predict the response of patients.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
38
Citations
NaN
KQI